BCLIライブシグナル | Getagraph.comで利益を最大化

買う 115331 min ago

@ $0.370

発行日: 9 2月 2024 @ 23:30

リターン: 44.61%

前回のシグナル: 2月 9 - 04:29

前回のシグナル: 売る

リターン: -6.68 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:38):

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases...

Stats
本日の出来高	33 674.00
平均出来高	1.01M
時価総額	36.58M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-0.0700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.340
ATR14	$0.00600 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Lebovits Chaim	Buy	15 000	Common Stock
2024-04-17	Dagher Ibrahim B.	Buy	0	Common Stock
2024-04-17	Dagher Ibrahim B.	Sell	0	Common Stock
2024-04-17	Dagher Ibrahim B.	Buy	0	Common Stock
2024-04-18	Lebovits Chaim	Buy	115 072	Common Stock

INSIDER POWER
100.00
Last 89 transactions
Buy: 3 045 109 \| Sell: 254 714

ボリューム相関

長: -0.07 (neutral)

短: -0.16 (neutral)

Signal:(50.682) Neutral

Brainstorm Cell 相関

10 最も正の相関
INTU	0.828
ECOR	0.811
TROO	0.81
USMC	0.81
ESPO	0.804
ADBE	0.803
XENT	0.803

10 最も負の相関
CYRN	-0.828

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Brainstorm Cell 相関 - 通貨/商品

-0.27
( neutral )

-0.34
( neutral )

0.00
( neutral )

0.20
( neutral )

Brainstorm Cell 財務諸表

Annual	2023
収益:	$0
総利益:	$-265 000 (0.00 %)
EPS:	$-0.400

FY	2023
収益:	$0
総利益:	$-265 000 (0.00 %)
EPS:	$-0.400

FY	2022
収益:	$0
総利益:	$-285 000 (0.00 %)
EPS:	$-0.650

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Brainstorm Cell

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.